Topics
July/August 2016 | What's New On The Anti-pdgf Front?
An Oral Drug for Treatment of AMD?
The potential for this proposed treatment option could be significant for many patients and their caregivers.
Carl C. Awh, MD
April 17, 2026
Phase 1 Data for Vamikibart Published in JAMA Ophthalmology
MeiraGTx Announces the Acquisition of XLRP Therapy From J&J
April 16, 2026
Experimental Light-Activated Therapy Shows Early Promise for Retinitis Pigmentosa
April 15, 2026
Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply for Ophthalmic Program
April 2026 Insert
Editorially independent supported by Abbvie and Regenxbio
April 2026 Supplement
Editorially independent content supported with advertising by EyePoint
Free Print Subscription
Email Newsletter
Conference Calendar
